當(dāng)前位置：首頁(yè) JCRQ2 期刊介紹(非官網(wǎng))

Clinics And Research In Hepatology And GastroenterologySCIE

國(guó)際簡(jiǎn)稱：CLIN RES HEPATOL GAS 參考譯名：肝病學(xué)和胃腸病學(xué)的診所和研究

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q2

基本信息：: ISSN：2210-7401; E-ISSN：2210-741X; 是否OA：未開(kāi)放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：FRANCE; 出版商：Elsevier Masson; 出版語(yǔ)言：English; 出版周期：6 issues/year; 出版年份：2011; 研究方向：GASTROENTEROLOGY & HEPATOLOGY

評(píng)價(jià)信息：: 影響因子：2.6; H-index：51; CiteScore指數(shù)：4.3; SJR指數(shù)：0.676; SNIP指數(shù)：0.616

發(fā)文數(shù)據(jù)：: Gold OA文章占比：27.16%; 研究類文章占比：73.87%; 年發(fā)文量：111; 自引率：0.0370...; 開(kāi)源占比：0.105; 出版撤稿占比：0; 出版國(guó)人文章占比：0.23; OA被引用占比：0.0018...

投稿咨詢加急見(jiàn)刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見(jiàn)問(wèn)題

英文簡(jiǎn)介Clinics And Research In Hepatology And Gastroenterology期刊介紹

Clinics and Research in Hepatology and Gastroenterology publishes high-quality original research papers in the field of hepatology and gastroenterology. The editors put the accent on rapid communication of new research and clinical developments and so called "hot topic" issues. Following a clear Editorial line, besides original articles and case reports, each issue features editorials, commentaries and reviews. The journal encourages research and discussion between all those involved in the specialty on an international level. All articles are peer reviewed by international experts, the articles in press are online and indexed in the international databases (Current Contents, Pubmed, Scopus, Science Direct).

Clinics and Research in Hepatology and Gastroenterology is a subscription journal (with optional open access), which allows you to publish your research without any cost to you (unless you proactively chose the open access option). Your article will be available to all researchers around the globe whose institution has a subscription to the journal.

期刊簡(jiǎn)介Clinics And Research In Hepatology And Gastroenterology期刊介紹

《Clinics And Research In Hepatology And Gastroenterology》自2011出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見(jiàn)解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：偏慢,4-8周
醫(yī)學(xué)
GASTROENTEROLOGY & HEPATOLOGY
SCIE
中科院4區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Clinics And Research In Hepatology And Gastroenterology Cite Score數(shù)據(jù)

CiteScore：4.3
SJR：0.676
SNIP：0.616

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Gastroenterology	Q2	77 / 167	54%

CiteScore 是由Elsevier(愛(ài)思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Clinics And Research In Hepatology And Gastroenterology 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	GASTROENTEROLOGY & HEPATOLOGY 胃腸肝病學(xué)	4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開(kāi)始，這個(gè)分區(qū)只是為了方便圖書(shū)管理及圖書(shū)情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Clinics And Research In Hepatology And Gastroenterology JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：GASTROENTEROLOGY & HEPATOLOGY	SCIE	Q2	67 / 143	53.5%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：GASTROENTEROLOGY & HEPATOLOGY	SCIE	Q2	70 / 143	51.4%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
France134
CHINA MAINLAND124
Italy36
GERMANY (FED REP GER)35
USA32
Spain22
Portugal11
Belgium10
Brazil9
Switzerland9

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial
Author: Liu, Dan-Ni; Wang, Qiu-Yan; Li, Pei -Yuan; Wu, Dong-Han; Pan, Jing; Chen, Zheng-Yi; Li, Yan-Qiang; Han, Xiang-Yang; Lan, Cheng; Tang, Jing; Tan, Yan; Mo, Cui-Yi; Yang, Wei-Zhong; Han, Jun-Ling; Huang, Xiao-Xi

Journal: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2023; Vol. 47, Issue 5, pp. -. DOI: 10.1016/j.clinre.2023.102125
2、Efficacy and safety of no-touch radiofrequency ablation for small hepatocellular carcinoma-a systematic review and single-arm meta-analysis
Author: Du, Fei; Zhang, Lingkai; Zhang, Yongxuan; Fan, Haining; Ren, Li

Journal: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2023; Vol. 47, Issue 1, pp. -. DOI: 10.1016/j.clinre.2022.102069
3、Metabolic-associated fatty liver disease and the risk of cardiovascular disease
Author: Zhang, Pengwei; Dong, Xianhui; Zhang, Wei; Wang, Shiyin; Chen, Chen; Tang, Jiake; You, Yao; Hu, Siqi; Zhang, Shenghui; Wang, Chunyi; Wen, Wen; Zhou, Mengyun; Tan, Tao; Qi, Guanming; Li, Li; Wang, Mingwei

Journal: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2023; Vol. 47, Issue 1, pp. -. DOI: 10.1016/j.clinre.2022.102063
4、The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy
Author: Wang, Manzhou; Sun, Limin; Han, Xinwei; Ren, Jianzhuang; Li, Hao; Wang, Wenhui; Xu, Wenze; Liang, Chao; Duan, Xuhua

Journal: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2023; Vol. 47, Issue 1, pp. -. DOI: 10.1016/j.clinre.2022.102060
5、Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019
Author: Tian, Hongzhan; Zhang, Kexin; Hui, Zongguang; Ren, Fangbing; Ma, Yanhui; Han, Fang; Sun, Xiaodong; Kan, Chengxia; Hou, Ningning

Journal: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2023; Vol. 47, Issue 1, pp. -. DOI: 10.1016/j.clinre.2022.102068
6、LncRNA ZFAS1 ameliorates injury led by non- alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation
Author: Liu, Lu; Sun, Sen; Li, Xiaohua

Journal: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2023; Vol. 47, Issue 1, pp. -. DOI: 10.1016/j.clinre.2022.102067
7、Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors
Author: Zhang, Lijie; Zhang, Xin; Li, Qing; Makamure, Joyman; Liu, Ziyi; Zhao, Dan; Li, Xin; Shi, Heshui; Zheng, Chuansheng; Liu, Fengyong; Liang, Bin

Journal: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2023; Vol. 47, Issue 2, pp. -. DOI: 10.1016/j.clinre.2022.102071
8、T lymphocyte-mediated pyroptosis: A new regulatory mechanism in non-viral liver disease
Author: Xiong, Wanyuan; Qian, Zibing; Mao, Xiaorong; Li, Junfeng

Journal: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 2023; Vol. 47, Issue 2, pp. -. DOI: 10.1016/j.clinre.2022.102070